Clinical Trials List
2019-02-01 - 2019-12-25
Phase II
Recruiting5
ICD-10C22.0
Liver cell carcinoma
ICD-10C22.2
Hepatoblastoma
ICD-10C22.3
Angiosarcoma of liver
ICD-10C22.4
Other sarcomas of liver
ICD-10C22.7
Other specified carcinomas of liver
ICD-10C22.8
Malignant neoplasm of liver, primary, unspecified as to type
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9155.0
Malignant neoplasm of liver, primary
-
Trial Applicant
National Health Research Institutes
-
Sponsor
-
Trial scale
Taiwan Multiple Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Shang-Hung Chen Division of Hematology & Oncology
- Yih-Jyh Lin Division of General Surgery
- 蘇哲民 Division of General Surgery
- Kwang-Yu Chang Division of Hematology & Oncology
- Li-Tzong Chen Division of Hematology & Oncology
- Hui-Jen Tsai Division of Hematology & Oncology
- 姜乃榕 Division of Hematology & Oncology
- 周宗慶 Division of General Surgery
- Nai-Jung Chiang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Gar-Yang Chau Division of General Surgery
- Hao-Jan Lei Division of General Internal Medicine
- Yi-Hsiang Huang Division of General Internal Medicine
- Chien-Wei Su Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
132 participants
-
Global
132 participants
